Skip to main content
PREDILIFE logo

PREDILIFE — Investor Relations & Filings

Ticker · ALPRE ISIN · FR0010169920 LEI · 9695006IK5NBKHQU9116 PA Human health and social work activities
Open in API
Filings indexed 150 across all filing types
Latest filing 2025-04-30 Report Publication Anno…
Country FR France
Listing PA ALPRE

About PREDILIFE

https://www.predilife.com/en/

PREDILIFE specializes in predictive medicine, developing solutions to assess an individual's risk of developing major diseases. The company's approach integrates medical data, such as genetic testing and imaging, with artificial intelligence and mathematical models to create personalized risk profiles. Its primary offerings are predictive health check-ups, including a specialized test for assessing the 5-year risk of breast cancer (MammoRisk®) and a multi-condition check-up that evaluates the risk for several common cancers (lung, prostate, colorectal, melanoma) and cardiovascular disease. Based on these risk profiles, PREDILIFE provides personalized follow-up and preventive recommendations. The company offers its end-to-end solution, which includes remote consultations, to businesses, insurers, and healthcare professionals to facilitate wider access to preventive care.

Recent filings

Filing Released Lang Actions
REPORT DE LA PUBLICATION DES RESULTATS ANNUELS 2024 ET DU RAPPORT FINANCIER ANNUEL 2024
Report Publication Announcement Classification · 1% confidence The document is a press release dated April 30, 2025, titled "REPORT DE LA PUBLICATION DES RESULTATS ANNUELS 2024 ET DU RAPPORT FINANCIER ANNUEL 2024" (Postponement of the Publication of 2024 Annual Results and 2024 Annual Financial Report). It explicitly states that the publication of the annual results and the annual financial report is being delayed and provides new target dates (May 15, 2025, and May 30, 2025, respectively). Since this document is an announcement *about* the timing of the release of other reports (Annual Results/Annual Financial Report), and not the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document length is short (1697 chars), supporting the 'announcement' classification over the full report (10-K or IR).
2025-04-30 French
Bilan semestriel au 31/12/2024 du contrat de liquidité PREDILIFE
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE 17 JANVIER 2025" and presents the "Bilan semestriel au 31/12/2024 du contrat de liquidité PREDILIFE" (Semi-annual statement as of 12/31/2024 for the PREDILIFE liquidity contract). It details the status of the liquidity contract, including shares and cash held, and provides a detailed transaction log (purchases and sales) for the second half of 2024. This type of regular disclosure regarding market making or liquidity provision activities is a specific regulatory requirement, often related to share transactions. Since it is a formal, periodic report on share activity managed under a specific agreement, it most closely aligns with filings related to share transactions or capital structure changes. Given the options, 'Transaction in Own Shares' (POS) covers share repurchase/issuance activities, which is the core subject matter here (even if it's managed by a third party for liquidity purposes). It is not a general earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it is highly specific to share liquidity management.
2025-01-17 French
PREDILIFE DOUBLE SON VOLUME DE VENTE EN 2024 ET ANTICIPE UNE FORTE CROISSANCE POUR 2025
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and dated January 8, 2025. It announces strong sales volume growth for the year 2024 and provides outlook/perspectives for 2025. This content—a summary of recent performance highlights intended for immediate public release—is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K), an interim report (IR), or a full transcript (CT). Although it discusses financial figures (sales volume), it explicitly states that the final 2024 revenue will be communicated later, confirming it is an initial results announcement rather than the full financial statement. FY 2024
2025-01-08 French
PREDILIFE ANNONCE LA RÉALISATION D'UNE LEVÉE DE FONDS DE 779 000 EUROS DANS LE CADRE DE SON OFFRE AU PUBLIC D'OBLIGATIONS À 8,5% PAR AN REMBOURSABLES IN FINE EN INTEGRALITÉ EN ESPÈCES OU EN ACTIONS
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) dated December 17, 2024, announcing the successful completion of a fundraising effort ("réalisation d'une levée de fonds de 779 000 euros") through the issuance of bonds convertible into shares (ORNANE). This explicitly details a financing activity, including the amount raised, the intended use of proceeds, and the resulting dilution calculations. This directly corresponds to the definition of a Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2024-12-17 French
Predilife lance une émission d'obligations de 2M EUR à un taux de 8,5% par an sur 5 ans
Capital/Financing Update Classification · 1% confidence The document is a press release dated November 12, 2024, announcing the launch of a public offering of convertible bonds (ORNANE) for 2 million euros to finance development and partnerships. Key terms like 'émission d'obligations' (bond issuance), 'Offre' (Offering), 'souscription' (subscription), and detailed financial terms (interest rate, maturity, conversion price) are present. This clearly indicates a fundraising or capital structure change activity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA/RNS), as it contains the core details of the financing event itself.
2024-11-12 French
Réalisation de l'apport partiel d'actif de MammoRisk à une valorisation de 202 M EUR
M&A Activity Classification · 1% confidence The document is a press release dated November 7, 2024, announcing the completion ('réalisation') of a partial asset transfer ('apport partiel d'actif') of the MammoRisk division to a subsidiary, valuing the asset at €202 million. This transaction involves a significant change in the company's structure and asset valuation, which falls under financing or capital structure changes. Reviewing the definitions, 'Capital/Financing Update (Code: CAP)' is the most appropriate category as it covers 'Updates on company fundraising, financing activities, or capital structure changes.' While it is a press release, its core subject matter is a major capital restructuring event, making CAP more specific than the general 'RPA' or 'RNS'. The document is not a formal regulatory filing like a 10-K or IR, but a specific corporate action announcement.
2024-11-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.